NCT06359379View on ClinicalTrials.gov

Ropidoxuridine as a Radiosensitizer in Newly Diagnosed IDH-Wildtype Glioblastoma With Unmethylated MGMT Promoter

PHASE2RecruitingINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

September 2, 2024

Primary Completion Date

August 31, 2026

Study Completion Date

February 28, 2027

Conditions
Glioblastoma, IDH-wildtype
Interventions
DRUG

Ropidoxuridine

Ropidoxuridine is administered daily, 5 days a week, for 7 weeks, starting one week prior to radiotherapy, and then concurrently with a standard 60 Gy radiotherapy, followed by a 4-week rest period.

Trial Locations (6)

15212

RECRUITING

Allegheny General Hospital, Pittsburgh

20007

RECRUITING

Lombardi Comprehensive Cancer Center, Washington D.C.

22903

RECRUITING

University of Virginia, Charlottesville

27599

RECRUITING

Lineberger Comprehensive Cancer Center, Chapel Hill

33176

RECRUITING

Miami Cancer Institute, Miami

07601

RECRUITING

John Theurer Cancer Center at the Hackensack University Medical Center, Hackensack

All Listed Sponsors
lead

Shuttle Pharmaceuticals, Inc.

INDUSTRY